1.A Cost-Benefit Analysis of Neonatal Screening Tests for Maple Syrup Urine Disease, Homocystinuria, Galactosemia, and Congenital Adrenal Hyperplasia.
Shin Young PARK ; Dong Il KIM ; Dong Hwan LEE
Journal of Genetic Medicine 2008;5(2):111-118
PURPOSE: Neonatal screening tests are increasingly being used forearly diagnosis of inborn errors of metabolism (IEM) in the hope of avoiding the severe developmental delay, acute illness, and death that may result from these diseases. In this study, a cost-benefit analysis was performed on the neonatal screening of maple syrup urine disease, homocystinuria, galactosemia, and congenital adrenal hyperplasia in Korea. MATERIALS AND METHODS: This study included 1,259,220 Korean newborns born between January 2005 to December 2007, who were screened for maple syrup urine disease, homocystinuria, galactosemia, and congenital adrenal hyperplasia. We calculated and compared the total costs in cases where these four screening tests were implemented, and those where they were not. RESULTS: There were no benefits to screening for maple syrup urine disease or homocystinuria due to their low prevalence for these two tests, the costs exceeded the benefits at benefit:cost ratios of 0.5:1 and 0.6:1, respectively. In contrast, benefits far exceed costs at a ratio of 4.1:1 for galactosemia and 2.9:1 for congenital adrenal hyperplasia. The average benefit:cost ratio for all four tests was 2.0:1. CONCLUSION: Neonatal screening tests for maple syrup urine disease, homocystinuria, galactosemia, and congenital adrenal hyperplasia are financially viable.
Acer
;
Adrenal Hyperplasia, Congenital
;
Cost-Benefit Analysis
;
Galactosemias
;
Homocystinuria
;
Humans
;
Infant, Newborn
;
Korea
;
Maple Syrup Urine Disease
;
Mass Screening
;
Metabolism, Inborn Errors
;
Neonatal Screening
;
Prevalence
2.A Case of Maple Syrup Urine Disease detected by Tandem Mass Spectrometry in Newborn Screening Test.
Chong Gwon O ; Young Soo JUNG ; Byoung Hoon YOO ; Dong Keun LEE ; In Seok LIM
Journal of the Korean Society of Neonatology 2003;10(1):88-93
Maple syrup urine disease (MSUD) is an autosomal recessive disorder. Impaired activity of the branched-chain 2-oxo acid dehydrogenase complex causes accumulation of branched-chain L-amino and 2-oxo acid that can exert neurotoxic effects. MSUD presents heterogeneous clinical and molecular phenotypes. Severity of the disease, ranging from classical to mild variant types, is commonly classified on the basis of indirect parameters, e.g. onset, leucine tolerance and/or residual enzyme activity in cell. Since early 1990's, tandem mass spectrometry has been applied to newborn screening, because it is amenable to population-wide testing for a large number of disorders of fatty acid, organic acid, and amino acid metabolism. And so, we report a case of MSUD in 15 days old boy detected by newborn screening using tandem mass spectrometry.
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)
;
Acer*
;
Humans
;
Infant, Newborn*
;
Leucine
;
Male
;
Maple Syrup Urine Disease*
;
Mass Screening*
;
Metabolism
;
Phenotype
;
Tandem Mass Spectrometry*
3.A Case of Maple Syrup Urine Disease Associated with Acrodermatitis Enteropathica-like Syndrome Due to Iisoleucine Deficinecy During Diet Therapy.
Ki Hyang MOON ; Oh Sook GWON ; Jung Im LEE ; Seong Woo RHO ; Seong Sook JEON ; Son Sang SEO
Journal of the Korean Pediatric Society 2001;44(4):469-474
Maple syrup urine disease(MSUD) is an autosomal recessive disorder involving the metabolism of the branched-chain amino acids(BCAA) such as leucine, isoleucine and valine. The disorder is due to a defect in branched-chain alpha-ketoacid dehydrogenase(BCKAD) and the classic form causes rapid progressive and overwhelming illness beginning in the first weeks of life, present with poor feeding, lethargy, change in muscle tone, acidosis, seizures and coma. The goal of therapy in acutely ill patients with MSUD is an immediate reduction in the plasma levels of the BCAAs and branched-chain ketoacids. In this report, we describe an infant with MSUD who was treated by dietary therapy alone. During the therapy, acrodermatitis enteropathica-like syndrome developed with low plasma isoleucine concentration while she was receiving a formula deficient in BCAAs.
Acer*
;
Acidosis
;
Acrodermatitis*
;
Amino Acids, Branched-Chain
;
Coma
;
Diet Therapy*
;
Diet*
;
Humans
;
Infant
;
Isoleucine
;
Lethargy
;
Leucine
;
Maple Syrup Urine Disease*
;
Metabolism
;
Plasma
;
Seizures
;
Valine
4.Antiangiogenic Activity of Acer tegmentosum Maxim Water Extract in Vitro and in Vivo.
Eok Cheon KIM ; So Hun KIM ; Shan Ji PIAO ; Tack Joong KIM ; Kiho BAE ; Han Sung KIM ; Soon Sun HONG ; Byoung Ick LEE ; Moonsuk NAM
Journal of Korean Medical Science 2015;30(7):979-987
Angiogenesis, the formation of new blood vessels, is critical for tumor growth and metastasis. Notably, tumors themselves can lead to angiogenesis by inducing vascular endothelial growth factor (VEGF), which is one of the most potent angiogenic factors. Inhibition of angiogenesis is currently perceived as one of the most promising strategies for the blockage of tumor growth. In this study, we investigated the effects of Acer tegmentosum maxim water extract (ATME) on angiogenesis and its underlying signal mechanism. We studied the antiangiogenic activity of ATME by using human umbilical vein endothelial cells (HUVECs). ATME strongly inhibited VEGF-induced endothelial cell proliferation, migration, invasion, and tube formation, as well as vessel sprouting in a rat aortic ring sprouting assay. Moreover, we found that the p44/42 mitogen activated protein (MAP) kinase signaling pathway is involved in the inhibition of angiogenesis by ATME. Moreover, when we performed the in vivo matrigel plug assay, VEGF-induced angiogenesis was potently reduced when compared to that for the control group. Taken together, these results suggest that ATME exhibits potent antiangiogenic activity in vivo and in vitro and that these effects are regulated by the extracellular regulated kinase (ERK) pathway.
Acer/*metabolism
;
Angiogenesis Inhibitors/*pharmacology
;
Animals
;
Cell Line, Tumor
;
Cell Movement/drug effects
;
Cell Proliferation/drug effects
;
Cell Survival
;
Extracellular Signal-Regulated MAP Kinases/*metabolism
;
Hep G2 Cells
;
Human Umbilical Vein Endothelial Cells/*drug effects
;
Humans
;
MAP Kinase Signaling System/drug effects
;
Mice
;
Mice, Inbred C57BL
;
Mitogen-Activated Protein Kinase 1/metabolism
;
Neoplasm Invasiveness/pathology
;
Neovascularization, Pathologic/*drug therapy/prevention & control
;
Nitric Oxide Synthase Type III/metabolism
;
Phosphorylation/drug effects
;
Plant Extracts/pharmacology
;
Rats
;
Rats, Sprague-Dawley
;
Transcription Factors/metabolism
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism